Sam Brusco, Associate Editor12.13.22
Moon Surgical, French-American pioneer in accessible surgical innovation, has completed 30 First-in-Human laparoscopy procedures using its Maestro system at CHU Saint-Pierre, a public university hospital in Brussels, Belgium.
Maestro was designed for surgeons and patients in the 18.8 million yearly soft tissue surgical procedures not currently supported by telerobotic systems. It is small, adaptable, and can be integrated into existing clinical workflows while giving the surgeon more control throughout a procedure.
The Maestro surgical robot was granted its first FDA clearance last week.
"I am thrilled to be part of this monumental accomplishment by Moon Surgical," Pr. Guy-Bernard Cadière, former Head of Surgery at CHU Saint-Pierre and a legendary laparoscopic and robotic surgeon, who performed all 30 laparoscopic surgeries using the Maestro System, told the press. "This technology is brilliant; it gave me more control throughout the procedure, keeping me confident and less fatigued by the end. Maestro is a great benefit for any surgeon, giving them the freedom to conduct each surgery in the most efficient manner."
Maestro aims to boost OR efficiency by enhancing existing surgical instruments and techniques while minimizing impact on OR turnover time, particularly valuable in high-volume procedures or facilities focused on maintaining procedural volume.
The 30 procedures were performed in 10 days and covered seven different clinical indications. 14 of the procedures were laparoscopic cholecystectomies (removal of the gallbladder to treat symptomatic gallstone disease). Other procedures included bariatric interventions, hernia repairs, colorectal surgeries, and gastric reflux surgery.
"This is another testament to how much the Maestro System can improve a surgeon's experience," said Anne Osdoit, CEO of Moon Surgical, and a partner in Sofinnova Partners' medtech accelerator, MD Start. "The results of our First-in-Human trial are a great validation of the value of the Maestro System in a real-life surgical setting. It is simply fantastic to see our system providing treatments to patients. There is no greater reward than this."
Maestro was designed for surgeons and patients in the 18.8 million yearly soft tissue surgical procedures not currently supported by telerobotic systems. It is small, adaptable, and can be integrated into existing clinical workflows while giving the surgeon more control throughout a procedure.
The Maestro surgical robot was granted its first FDA clearance last week.
"I am thrilled to be part of this monumental accomplishment by Moon Surgical," Pr. Guy-Bernard Cadière, former Head of Surgery at CHU Saint-Pierre and a legendary laparoscopic and robotic surgeon, who performed all 30 laparoscopic surgeries using the Maestro System, told the press. "This technology is brilliant; it gave me more control throughout the procedure, keeping me confident and less fatigued by the end. Maestro is a great benefit for any surgeon, giving them the freedom to conduct each surgery in the most efficient manner."
Maestro aims to boost OR efficiency by enhancing existing surgical instruments and techniques while minimizing impact on OR turnover time, particularly valuable in high-volume procedures or facilities focused on maintaining procedural volume.
The 30 procedures were performed in 10 days and covered seven different clinical indications. 14 of the procedures were laparoscopic cholecystectomies (removal of the gallbladder to treat symptomatic gallstone disease). Other procedures included bariatric interventions, hernia repairs, colorectal surgeries, and gastric reflux surgery.
"This is another testament to how much the Maestro System can improve a surgeon's experience," said Anne Osdoit, CEO of Moon Surgical, and a partner in Sofinnova Partners' medtech accelerator, MD Start. "The results of our First-in-Human trial are a great validation of the value of the Maestro System in a real-life surgical setting. It is simply fantastic to see our system providing treatments to patients. There is no greater reward than this."